KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non Operating Income (2018 - 2025)

Acadia Pharmaceuticals has reported Other Non Operating Income over the past 8 years, most recently at $596000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 3.65% year-over-year to $596000.0; the TTM value through Dec 2025 reached $2.4 million, up 30.06%, while the annual FY2025 figure was $2.4 million, 30.06% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $596000.0 at Acadia Pharmaceuticals, up from $593000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $4.8 million in Q1 2023 and troughed at -$1.2 million in Q2 2023.
  • A 5-year average of $783368.4 and a median of $576000.0 in 2024 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: plummeted 379.21% in 2022 and later soared 1325.0% in 2023.
  • Year by year, Other Non Operating Income stood at $1.6 million in 2021, then dropped by 4.93% to $1.5 million in 2022, then decreased by 2.27% to $1.5 million in 2023, then crashed by 61.87% to $575000.0 in 2024, then increased by 3.65% to $596000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for ACAD at $596000.0 in Q4 2025, $593000.0 in Q3 2025, and $594000.0 in Q2 2025.